Johnson & Johnson wins FDA nod for intravesical drug delivery tech
September 9, 2025
Johnson & Johnson (NYSE:JNJ) announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.
SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ — Patients who suffer from chronic conditions often require continuous injections of drugs, which is quite painful and often inconvenient.
SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ — Willow Innovations, Inc. (Willow), the Femtech leader and inventor of the first fully in-bra wearable breast pump, is once again revolutionizing the pumping experience with the launch of its newest innovation.
CAMPBELL, Calif., Sept. 9, 2025 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, today announced the commercial release of its new wearable ECG sensor adhesive that improves the detection of p-waves during ambulatory cardiac monitoring
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.
Stryker (NYSE: SYK)+
today announced the launch of its recently FDA-cleared Incompass total ankle system.
Varian announced its Embozene microspheres have received CE mark for genicular artery embolisation (GAE) to treat knee osteoarthritis.
The FDA’s clearance of LIBERTY follows the completion of Microbot’s pivotal trial in April 2025, achieving a 100% success rate in robotic navigation.
ARC‑EX is the first system to receive a CE Mark in Europe specifically for improving hand and arm strength and sensation in adults with chronic, incomplete spinal cord injury.
Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flareup, and release drugs exactly where and when they are needed.